Evidence & Research Status
In late May 2026, Eli Lilly released the first Phase 3 results from the TRIUMPH-1 trial, marking a pivotal moment for GLP-1 research. Retatrutide — a first-in-class triple receptor agonist targeting…
Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.
In late May 2026, Eli Lilly released the first Phase 3 results from the TRIUMPH-1 trial, marking a pivotal moment for GLP-1 research. Retatrutide — a first-in-class triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — demonstrated 28.3% mean body weight reduction at the 12mg dose after 80 weeks. Researchers are now asking the central question: how does this compare to tirzepatide, Lilly’s established dual GLP-1/GIP agonist?
Update — July 10, 2026: A TRIUMPH-1 sleep apnea substudy reported in June 2026 found retatrutide associated with a 60.6% reduction in apnea-hypopnea index (AHI) among trial participants with obstructive sleep apnea, adding a new endpoint to the compounds Phase 3 research profile alongside the weight-loss and T2D data below.
Update — August 7, 2026
For context on the July 2026 sleep-apnea substudy noted above: tirzepatide has its own dedicated OSA program, SURMOUNT-OSA, purpose-built around sleep-apnea endpoints rather than as a substudy. That trial reported AHI reductions of 50.7%–58.7% depending on dose and PAP-therapy use — somewhat below retatrutide’s 60.6% substudy figure, though the two trials used different designs and populations, so the comparison is directional, not head-to-head. AHI reduction is typically read against severity bands (mild 5–15, moderate 15–30, severe 30+ events/hour), so the same relative reduction moves different patients across different absolute thresholds depending on baseline severity.
Update — July 14, 2026: Lilly’s Phase 3 TRIUMPH-4 trial reported topline results in July 2026, this time in participants with obesity/overweight and knee osteoarthritis. Researchers observed 28.7% mean weight loss at 68 weeks on the 12mg dose (26.4% at 9mg) versus 2.1% for placebo, alongside a 75.8% reduction in WOMAC knee-pain scores and improved physical function measures. A new safety signal, dysesthesia (altered sensation), emerged in this trial — investigators described it as generally mild and rarely leading to discontinuation. Seven additional Phase 3 trials (obesity, T2D, osteoarthritis, sleep apnea, chronic low back pain, MASLD, and cardiometabolic outcomes) are expected to report through the rest of 2026. (Source: Eli Lilly investor release)
Update — July 16, 2026: A direct three-way comparison is now possible across published Phase 3 obesity-population data: retatrutide’s TRIUMPH-1 trial produced 28.3% mean weight loss (n=2,339) versus 22.5% for tirzepatide (SURMOUNT program) and 14.9% for semaglutide (STEP program) in comparable populations. These are cross-trial comparisons rather than head-to-head randomized data, so differences in patient population and trial design may account for some of the gap. (Source: Lola Health, TRIUMPH Program summary)
Update — July 16, 2026 (FDA compounding status): FDA’s own guidance states retatrutide fails all three eligibility criteria for 503A/503B compounding — it has no USP/NF monograph, is not a component of any FDA-approved drug, and has never appeared on the drug shortage list — meaning there is currently no legal pathway to compound it for patient dispensing. FDA has also confirmed it has received 990 adverse-event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide through May 31, 2026, largely linked to dosing errors from multi-dose vials rather than the compounds themselves. Portal to Wellness does not compound or dispense any product for human use; all compounds referenced here are sold strictly as Research Use Only. (Source: FDA, GLP-1 Concerns page)
Key Takeaways
- Retatrutide and tirzepatide work through different combinations of incretin receptors.
- TRIUMPH-1 Phase 3 data offers a direct data point for comparing the two compounds.
- Side-by-side findings highlight where the two diverge most in reported outcomes.
- Both remain prescription or investigational compounds — PTW sells research-grade material for laboratory use only.
Understanding the Receptor Mechanism Difference
The distinction between retatrutide and tirzepatide begins at the receptor level — and that difference may explain much of the efficacy gap observed in trial data.
Tirzepatide: Dual GIP/GLP-1 Agonism
Tirzepatide acts on two receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). Large-scale SURMOUNT trial data showed approximately 20–22% mean body weight reduction at 72 weeks in participants with obesity without diabetes. Tirzepatide (Mounjaro/Zepbound) is currently FDA-approved for both type 2 diabetes management and chronic weight management.
Retatrutide: Triple GLP-1/GIP/Glucagon Agonism
Retatrutide adds glucagon receptor (GCGR) agonism to the dual GIP/GLP-1 profile. Researchers hypothesize that glucagon receptor engagement accelerates fat oxidation and increases energy expenditure beyond what GLP-1/GIP agonism alone achieves — mechanisms that may explain the incremental weight reduction observed above tirzepatide. Phase 2 data had already suggested 24–26% weight loss; Phase 3 TRIUMPH-1 results confirmed and extended this signal.
TRIUMPH-1 Phase 3 Data: Key Findings
TRIUMPH-1 enrolled 2,339 participants across a multicenter, randomized, placebo-controlled design. The 80-week trial reported positive top-line results on May 21, 2026. (Source: Clinical Trials Arena)
| Dose | Mean Weight Reduction (80 weeks) |
|---|---|
| Placebo | 3.9% |
| 4 mg | 17.6% |
| 9 mg | 23.7% |
| 12 mg (highest dose) | 28.3% |
Adverse Events and Discontinuation
Trial data showed that 11.3% of participants in the 12mg cohort discontinued treatment due to adverse events, compared with 4.9% in the placebo group. The adverse event profile was consistent with GLP-1 class effects: primarily gastrointestinal symptoms including nausea, vomiting, and diarrhea — most pronounced during dose escalation phases. Researchers note this discontinuation rate is higher than observed in tirzepatide trials at comparable efficacy doses.
Diabetes Subpopulation: TRANSCEND-T2D-1
A separate trial, TRANSCEND-T2D-1, published March 2026, found that participants with type 2 diabetes mellitus who received retatrutide 12mg lost an average of 16.8% of body weight at 40 weeks — meaningful efficacy in a population where metabolic factors typically limit weight loss magnitude.
Retatrutide vs. Tirzepatide: Side-by-Side Comparison
| Parameter | Tirzepatide | Retatrutide |
|---|---|---|
| Receptors targeted | GLP-1R + GIPR | GLP-1R + GIPR + GCGR |
| Peak weight reduction (Phase 3) | ~22% at 15mg (72 weeks) | ~28.3% at 12mg (80 weeks) |
| US regulatory status | FDA-approved (Mounjaro/Zepbound) | NDA expected Q4 2026; market ~Q1-Q2 2028 |
| Discontinuation (highest dose) | ~7–8% | 11.3% |
| Cardiovascular outcome trial | SURMOUNT-MMO (ongoing) | TRANSCEND CV (ongoing) |
Open Questions for Researchers
- Lean mass impact: Phase 2 body composition substudies for retatrutide are ongoing. Researchers are actively investigating whether the additional glucagon receptor engagement affects lean mass and muscle preservation differently than dual agonists.
- Cardiovascular mortality data: No head-to-head trial comparing retatrutide and tirzepatide on MACE (major adverse cardiovascular events) outcomes currently exists. SURMOUNT-MMO (tirzepatide) and TRANSCEND CV (retatrutide) are both ongoing, with results expected in the coming years.
- Long-term metabolic adaptations: The glucagon receptor component raises research questions about potential changes in hepatic glucose output and lipid metabolism over multi-year timeframes in subjects with varying metabolic baselines.
- Dose-response in specific populations: How metabolic status at baseline affects response magnitude remains an active area of inquiry, particularly following the TRANSCEND-T2D-1 findings in type 2 diabetes.
Regulatory Timeline for Retatrutide
As of July 2026, Eli Lilly has not yet filed an NDA for retatrutide. The company has indicated a Q4 2026 filing target, with FDA review anticipated through 2027 and potential market availability in Q1-Q2 2028. Researchers tracking this compound can monitor the ClinicalTrials.gov registration for ongoing study updates.
All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.
📚 Part of our GLP-1 & Metabolic Research Guide research guide.
Update — July 27, 2026
Lilly reported two additional Phase 3 retatrutide trials this week, on top of the TRIUMPH-1 data discussed above:
- Adults with severe obesity and established cardiovascular disease: average 22.6% weight loss at the highest dose over 80 weeks.
- Adults with obesity and type 2 diabetes: average 20.8% weight loss, alongside roughly a 1.6 percentage-point reduction in A1C.
A limited cardiovascular-events analysis showed numerically more major cardiovascular events (MACE-3: cardiovascular death, heart attack, or stroke) in the retatrutide arm than placebo (27 vs. 23 events; hazard ratio 1.12, 95% CI 0.64–1.96) — a difference that is not statistically significant and comes from a trial that was not designed or powered to answer a cardiovascular-safety question. This is a signal to watch in future dedicated outcome trials, not evidence that retatrutide increases cardiovascular risk.
Lilly says it is completing its CMC data package and plans to submit a Biologics License Application to the FDA in Q1 2027. Retatrutide remains investigational and is not FDA-approved; nothing about a planned filing changes its current regulatory or research-use status.
Update — August 3, 2026
On July 23, 2026, Lilly reported topline results for TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3, adding to the TRIUMPH-1 data referenced above. No U.S. application has been filed yet: Lilly is targeting a BLA filing in Q1 2027 after completing its chemistry-manufacturing-controls (CMC) package, a later timeline than earlier researcher expectations. Source: TRIUMPH Program Results 2026.